United Kingdom

People: AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

24 May 2019
Change (% chg)

$0.32 (+1.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Scopelianos, Angelo 

Dr. Angelo G. Scopelianos is Vice President - Research and Development of the Company. Prior to joining AxoGen, Dr. Scopelianos was an independent consultant specializing in medical devices. He began consulting after a 24-year career at Johnson & Johnson. As Senior Vice President of Research and Development he led a world class corporate team comprised of multidisciplinary scientists, engineers, and medical doctors responsible for developing a wide range of life-enhancing products and technologies across the company’s medical device, pharmaceutical, and consumer organizations. He joined Johnson & Johnson after research leadership positions at EI Dupont de Nemours in Wilmington, Delaware and Pennwalt Corporation. Dr. Scopelianos received his doctorate degree in Organic Chemistry from Pennsylvania State University, following completion of a Bachelor of Science degree from the State University of New York – Oneonta. He holds over 35 U.S. patents and numerous international patents and his awards include the Outstanding Science Alumni Award by Pennsylvania State University; the Scientific Leadership Award in Biomaterials Science awarded by a consortium of NJ research universities: Rutgers University, Princeton University & NJ Institute of Technology; the Johnson & Johnson Philip B. Hofmann Award for technical achievements in scientific research; and Honorary Doctor of Science Degree bestowed by the State University of New York.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --